Centre for Biological Signalling Studies

Cancer Immunotherapy

Cancer Immunotherapy is a very innovative and powerful approach to utilize the capabilities of the immune system to fight against cancers. Our expertise in studying the functions of the TCR can now be used to optimize strategies for such therapeutical approaches. We follow two lines of research:

1) We are part of the EU consortium EN-ACT2ING and will develop novel chimeric antigen receptors to be used in adoptive T cell therapies against hematopoietic cancers. For more information please visit:

2) We are collaborating with TCR2 Therapeutics Inc., an immuno-oncology company located in Cambridge, Massachusetts to apply our detailed insight into the TCR structure and functioning to support development of novel engineered T cell therapies. For more information please visit



Juraske C, Krissmer SM, Teuber ES, Parigiani MA, Strietz J, Wesch D, Kabelitz D, Minguet S & Schamel WW (2024) Reprogramming of human γδ T cells by expression of an anti-CD19 TCR fusion construct (εTRuC) to enhance tumor killing. J Leukoc Biol 115: 293-305

Velasco Cárdenas RM, Brandl SM, Meléndez AV, Schlaak AE, Buschky A, int. al, Bengsch B, Schamel WW*, Minguet S* (2023) Harnessing CD3 diversity to optimize CAR T cells. Nat Immunol 24: 2135-2149. * co-last authors

Hartl FA, Beck-Garcìa E, Woessner NM, Flachsmann LJ, Cárdenas RMV, Brandl SM, Taromi S, Fiala GJ, int. al, Günther S, Schamel WW*, Minguet S* (2020) Noncanonical binding of Lck to CD3ε promotes TCR signaling and CAR function. Nat Immunol 21: 902-913. * co-last authors

Baeuerle PA, Ding J, Patel E, Thorausch N, Horton H, Gierut J, Scarfo I, Choudhary R, Kiner O, Krishnamurthy J, et al (2019) Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat Commun 10: 2087

Juraske C, Wipa P, Morath A, Hidalgo JV, Hartl FA, Raute K, Oberg HH, Wesch D, Fisch P, Minguet S, Pongcharoen S, Schamel WW (2018) Anti-CD3 Fab Fragments Enhance Tumor Killing by Human γδ T Cells Independent of Nck Recruitment to the γδ T Cell Antigen Receptor. Front Immunol 9: 1579.

Dopfer EP, Hartl FA, Oberg HH, int. al, Adams EJ, Minguet S, Wesch D, Fisch P, Schamel WW (2014) The CD3 conformational change in the γδ T cell receptor is not triggered by antigens but can be enforced to enhance tumor killing. Cell Rep 7: 1704-1715.